The importance of evaluating effects of FAP-RLT in an immunocompetent setting is further emphasized by recent findings of FAP as a potential predictive biomarker for PD-1 blockade in non-small cell lung cancer patients [28], which highlights the immunosuppressive role of FAP or FAP + cells. This evidence concerns the gene FAP and non-small cell lung carcinoma.